...of its internal RSV vaccine mRNA-1345, which it will evaluate in adults and children.BARDA awards Vaxxas...

...IV formulation of ofatumumab is approved as Arzerra to treat CLL. Merck exercises option for Vaxxas...
...develop and commercialize an undisclosed vaccine using the High-Density Microarray Patch (HD-MAP) platform from Vaxxas Pty. Ltd. Vaxxas...
...lum001) Oncotype DX breast cancer assay BeiGene Ltd. Novartis AG Antibe Therapeutics Inc. Mirum Pharmaceuticals Inc. Exact Sciences Corp. Merck & Co. Inc. Vaxxas Pty. Ltd. Aveo...

...Gates Foundation grants Vaxxas $5M for low-dose vaccine patch Vaxxas Pty. Ltd. received a $5 million grant Tuesday...
...vaccines can be stored at 40°C for at least 12 months. Also on Tuesday, a Vaxxas-led...
...which delivers six times more antigen -- from the CSL Ltd. unit Seqirus Pty Ltd. Vaxxas...

...of its needle-free Nanopatch technology to deliver an approved flu vaccine with an undisclosed partner. Vaxxas...
...World Health Organization to perform preclinical studies using Nanopatch to deliver polio vaccine. In 2012 Vaxxas...
...two additional undisclosed vaccine candidates (see BioCentury Extra, Oct. 8, 2012) . Several investors in Vaxxas'...

...human antibody candidates, potentially including bispecific antibody candidates, across all disease areas (deal expansion) Jan-13 Vaxxas Pty. Ltd....

...Vaxxas granted Merck exclusive, worldwide rights to develop and commercialize an undisclosed Merck vaccine using Vaxxas'...
...funding. Vaxxas is eligible for milestones, plus royalties. The companies declined to disclose details. Separately, Vaxxas...
...first CEO. Hoey was most recently VP of business development at PathoGenetiX Inc. (Woburn, Mass.). Vaxxas Pty. Ltd....

...Merck & Co. Inc. (NYSE:MRK) exclusive, worldwide rights to develop and commercialize a vaccine using Vaxxas'...
...funding. Vaxxas is eligible for milestones, plus royalties. The companies declined to disclose details. Separately, Vaxxas...

...Australian investment in new vaccine company Vaxxas Pty Ltd. The Cambridge, Mass., firm participated in Vaxxas'...
...Brandon Capital Partners; the Medical Research Commercialization Fund (MRCF); and the Brisbane Angels also participated. Vaxxas...
...board, along with Paul Kelly of OneVentures and Stephen Thompson of Brandon Capital. Onsi said Vaxxas...